Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth

Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chiao-Yun, Lee, Li-Yu, Wang, Tzu-Hao, Hsu, Cheng-Lung, Tsai, Chia-Lung, Chao, Angel, Lai, Chyong-Huey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678831/
https://www.ncbi.nlm.nih.gov/pubmed/31330844
http://dx.doi.org/10.3390/cancers11071025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678831/
https://www.ncbi.nlm.nih.gov/pubmed/31330844
http://dx.doi.org/10.3390/cancers11071025

Ejemplares similares